Factor VIII inhibitor bypassing activity (FEIBA) – addressing safety issues
- 23 October 2007
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 14 (1) , 39-43
- https://doi.org/10.1111/j.1365-2516.2007.01594.x
Abstract
Bypassing therapy is usually necessary to control or prevent bleeding episodes in patients with haemophilia A or B and high-titre inhibitors. Factor VIII inhibitor bypassing activity (FEIBA) has a long history of successful use in the acute, surgical and prophylactic treatment settings, but safety concerns have made some reluctant to administer this bypassing agent. A review of the literature and clinical trial data show that FEIBA has a low prevalence of thrombosis, a low prevalence of anamnesis that does not impact haemostatic efficacy and an excellent record of pathogen safety and clinical tolerability.Keywords
This publication has 28 references indexed in Scilit:
- Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experienceHaemophilia, 2007
- Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitorsHaemophilia, 2007
- Inhibitor challenges in the paediatric settingHaemophilia, 2006
- Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodiesHaemophilia, 2005
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity-reply to a rebuttalJournal of Thrombosis and Haemostasis, 2005
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity-a rebuttalJournal of Thrombosis and Haemostasis, 2005
- Activated prothrombin complex concentrate (FEIBA®) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experienceHaemophilia, 2004
- Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’Vox Sanguinis, 1996
- Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion, 1990
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981